摘要
耐多药结核病(MDR-TB)需采用二线抗结核药物治疗,是目前全球范围内结核病防控工作面临的主要挑战。环丝氨酸抗结核分枝杆菌作用较强,世界卫生组织(WHO)于2011年推荐环丝氨酸作为MDR-TB的二线核心口服抗结核药物之一,但近年来结核分枝杆菌对环丝氨酸耐药增多且具体耐药机制尚未完全明确。本文综述了结核分枝杆菌耐环丝氨酸相关基因,旨在为结核分枝杆菌对环丝氨酸的耐药机制研究提供参考。
MDR-TB requires second-line anti-tuberculosis drugs,which is the main challenge for tuberculosis prevention and control all of the world. Due to fairly strong anti-tuberculosis effect,cycloserine was recommended as one of second-line core oral anti-tuberculosis drugs by WHO in 2011,but drug resistance to cycloserine gradually increased in recent years,and the resistance mechanism is not completely understood so far. This paper reviewed the drug resistance related genes of Mycobacterium tuberculosis to cycloserine,to provide a reference for the research on resistance mechanism to cycloserine.
作者
何兴
陈玲
HE Xing;CHEN Ling(The Second Department of Respiratory Medicine,the Affiliated Hospital of Zunyi Medical College,Zunyi 563003,China)
出处
《实用心脑肺血管病杂志》
2018年第11期25-27,31,共4页
Practical Journal of Cardiac Cerebral Pneumal and Vascular Disease
基金
国家自然科学基金资助项目(81760003)
关键词
结核分枝杆菌
结核
抗多种药物性
广泛耐药结核
环丝氨酸
基因
突变
综述
Mycobacterium tuberculosis
Tuberculosis,multidrug-resistant
Extensively-resistant tuberculosis
Cycloserine
Gene
Mutation
Review
